Chemokines are a family of chemotactic cytokines that activate specific G-protein-coupled 7-transmembrane receptors. 10 They are central players in processes of vascular inflammation by recruitment of leukocytes, leading to progression of atherosclerosis and plaque destabilization. 11, 12 Accumulating literature points to a delicate role of chemokines in thrombogenesis. 13 Members of both the CC and CXC chemokine families have been described to activate platelets via their respective receptors. 14 However, the exact signaling mechanisms of platelet activation by inflammatory chemokines are still unknown.
The newly discovered chemokine of the CXC family, CXCL16, has been proposed as an important pathogenic mediator in inflammatory diseases, including rheumatoid arthritis, glomerulonephritis, or prostate cancer. 15 CXCL16 activates its unique receptor CXC motif receptor 6 (CXCR6; originally cloned as BONZO), which is expressed in numerous cells, predominantly including leukocytes. 16, 17 CXCR6 promotes atherosclerosis by supporting T-cell homing and macrophage accumulation in the aortic wall as well as aortic smooth muscle cell proliferation. 18, 19 Intracellular signaling, followed by an activation of CXCR6 by CXCL16, was shown to involve phosphatidylinositide 3-kinase (PI3K) and its downstream effector Akt (protein kinase B). 18, 20 CXCL16 is produced by several inflammatory cells preferentially expressed within atherosclerotic plaques, including macrophages, dendritic cells, smooth muscle cells, or lymphocytes. 21 Unlike the majority of chemokines, which are soluble and secreted, CXCL16 is expressed in 2 distinct forms. As surface-expressed transmembrane protein, CXCL16 (also termed as scavenger receptor that binds phosphatidylserine and oxidized lipoprotein [SR-PSOX]) can function as scavenger receptor for phosphatidylserine and oxidized low-density lipoproteins. [22] [23] [24] A soluble form of CXCL16, constitutively released by proteolytic cleavage of the chemokine domain involving a disintegrin and metalloproteinase 10 and a disintegrin and metalloproteinase 17, 25 promotes directed migration of CXCR6 + inflammatory cells to atherosclerotic lesions. 26 Recently, we found that CXCL16 is surface-expressed on platelets and is released on platelet stimulation. 27 Furthermore, we could show that platelet surface expression of CXCL16 was significantly enhanced in platelets obtained from patients with acute coronary syndrome (ACS) compared with platelets from patients with stable angina pectoris. 27 Other recent studies described CXCL16 as a positively associated marker of inflammation and progression of coronary atherosclerosis, particularly ACS. 28, 29 Furthermore, increased CXCL16 levels were demonstrated to be associated with long-term mortality in patients with ACS. 10 Although platelets are known to be the major players in the pathogenesis of atherothrombosis, 5 nothing is known about the influence of CXCL16 on platelet function.
The present study explored the functional significance of CXCL16 for platelet activation. Furthermore, the role of PI3K/ Akt signaling, downstream of the CXCL16 receptor CXCR6, in the regulation of CXCL16-sensitive platelet functions was addressed, as well as the underlying mechanism of CXCL16induced platelet activation and adhesion was examined.
Methods

Chemicals and Antibodies
Platelets were activated using recombinant human or murine CXCL16 (R&D Systems), ADP (Sigma-Aldrich), thrombin (Calbiochem), or collagen-related peptide (Richard Farndale). Fibrinogen (Enzyme Research Laboratories) was used for aggregation studies. For pharmacological inhibition of PI3K and Akt signaling pathway, we used wortmannin (Wm), LY294002 (LY), and SH-6 (all from Calbiochem), as described previously. 30 Purinergic receptors P 2 Y 1 and P 2 Y 12 were antagonized with MRS2179 (Tocris Bioscience) and Cangrelor (AR-C69931MX; The Medicines Company), thromboxane synthesis was inhibited by indomethacin (Calbiochem), and apyrase (Sigma-Aldrich) was used for enzymatic degradation of extracellular ADP.
Preparation of Human Platelets
Human platelets were isolated as described previously. 9 Blood from healthy volunteers was collected in acid-citrate-dextrose buffer and centrifuged at 200g for 20 minutes. The obtained platelet-rich plasma was added to modified Tyrode-HEPES buffer (137 mmol/L NaCl, 2.8 mmol/L KCl, 12 mmol/L NaHCO 3 , 5 mmol/L glucose, 0.4 mmol/L Na 2 HPO 4 , 10 mmol/L HEPES, 0.1% bovine serum albumin, pH 6.5). After centrifugation at 900g for 10 minutes and removal of the supernatant, the resulting platelet pellet was resuspended in Tyrode-HEPES buffer (pH 7.4, supplemented with 1 mmol/L CaCl 2 ).
Mice
Gene-targeted mice lacking functional Akt1/protein kinase Bα (akt1 −/− ) or Akt2/protein kinase Bβ (akt2 −/− ), as well as their wildtype littermates, were generated as described previously. 31, 32 For intravital microscopy, C57BL/6J (Charles River) mice were used. CXCR6-deficient mice (cxcr6 −/− ) and their respective wild-type littermates (cxcr6 +/+ ) were purchased from Jackson Laboratories. All animal experiments were conducted according to the German law for the care and use of laboratory animals and were approved by local authorities.
Preparation of Mouse Platelets
Platelets were obtained from 10-to 12-week-old akt1 −/− and akt1 +/+ mice as well as akt2 −/− and akt2 +/+ mice or cxcr6 −/− and cxcr6 +/+ mice of either sex. The mice were anesthetized with ether, and blood was drawn from the retro-orbital plexus into heparinized tubes. Blood parameters were analyzed with pocH-100iv automatic hematology analyzer (Sysmex). Platelet-rich plasma was obtained by centrifugation at 260g for 5 minutes. Platelet-rich plasma was then centrifuged at 640g for 5 minutes to pellet the platelets. After 2 further washing steps, the pellet of washed platelets was resuspended in modified Tyrode-HEPES buffer (pH 7.4, supplemented with 1 mmol/L CaCl 2 ).
Reverse-Transcriptase Polymerase Chain Reaction Analysis
CXCR6 mRNA expression in human platelets, as well as in murine platelets of CXCR6-or Akt-deficient platelets and their wildtype littermates, was determined as described in the Online Data Supplement Methods. 
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Western Blot Analysis
Western blot analysis of CXCR6 expression, as well as activationdependent Akt phosphorylation in murine and human platelets, was performed as described in the Online Data Supplement Methods.
Flow Cytometry
P-selectin expression was measured using a fluorescein isothiocyanate-labeled mouse anti-human P-selectin monoclonal antibody (Clone AK-4; BD Biosciences). Activated integrin α IIb β 3 was quantified through binding of the fluorescein isothiocyanate-labeled mouse anti-human monoclonal antibody PAC-1 (BD Biosciences). Expression of CXCR6 was analyzed using a PE-labeled mouse antihuman CXCR6 monoclonal antibody (Clone 56811, R&D Systems). Suitable isotype controls were used for each antibody. Two-color analysis of mouse platelet activation was conducted using fluorophore-labeled antibodies for P-selectin expression (Wug.E9-FITC) and the active form of α IIb β 3 integrin (JON/A-PE), as described previously. 2
Immunofluorescence and Confocal Microscopy
CXCR6 expression and activation-dependent P-selectin exposure in human platelets were determined as described in the Online Data Supplement Methods.
Aggregometry
Light transmission aggregometry (Model 700; Chrono-Log) was performed with isolated human platelets (2.5×10 5 /μL). After calibration, agonists were added at the indicated concentrations and aggregation was measured for 10 minutes with a stir speed of 1000 rpm at 37°C. The extent of aggregation was quantified in percentage of light transmission. The data analysis was performed with AGGRO/LINK8 software (Chrono-Log).
Dynamic Platelet Adhesion In Vitro
Adhesion experiments under flow conditions were performed as described previously. 33 Human umbilical vein endothelial cells (HUVECs) from an early passage of culture were grown to confluency, and 5×10 5 cells were attached on gelatin-coated glass slides by overnight incubation in complete endothelial cell basal medium (PAA). Washed human platelets were perfused over the HUVEC monolayer in a flow chamber model (Oligene) at high arterial shear rates (2000 −s ), and the cellular interaction events were recorded with a charge-coupled device camera (Carl Zeiss) with ×40 magnification, followed by analysis of the number of adherent platelets per highpower field.
Platelet Adhesion After Carotis Ligation In Vivo
Intravital fluorescence microscopy was performed as described previously. 34 In brief, C57BL/6 mice were anesthetized by injection of midazolame (5 mg/kg body weight; Ratiopharm), medetomidine (0.5 mg/kg body weight, Pfizer), and fentanyl (0.05 mg/kg body weight; CuraMed Pharma). The A. carotid com. was dissected free, and diacetate carboxyfluorescein-labeled platelets treated as indicated were injected intravenously before carotid artery ligation. Before and after injury, the platelet-vascular wall interactions were visualized by in vivo video microscopy.
Statistical Analysis
As indicated, data are provided as means±SD or SEM, and n represents the number of experiments. All data were tested for significance using Student t test or 1-way ANOVA with the Dunnett post hoc test. Only results with P<0.05 and P<0.01 were considered statistically significant.
Results
In an initial experiment, platelet expression of CXCR6 was analyzed. Reverse-transcriptase polymerase chain reaction analysis, as well as confocal microscopy, Western blotting, and flow cytometry of human and murine platelets, revealed that the CXCL16-specific receptor CXCR6 (BONZO) is highly expressed in platelets ( Figure 1 ). Because prostate cancer cell lines are well-known for high CXCR6 expression, 15, 20, 35 DU145 cells served as positive control.
According to flow cytometric analysis, stimulation of platelets in vitro with CXCL16 (50, 100, and 200 ng/mL) significantly enhanced the expression of P-selectin (200 ng/ mL: 92.8 ± 15.8 vs 27.6 ± 13.2; P<0.01) and activated integrin α IIb β 3 (200 ng/mL: 38.7 ± 8.9 vs 2.5 ± 2.3; P<0.01) at the platelet surface (Figure 2A-2C ). Confocal microscopy revealed degranulation as well as profound reorganization of actin cytoskeleton and shape change of platelets treated with increasing concentrations of CXCL16 ( Figure 2B ). In all experiments described, stimulation with low-dose ADP (5 μmol/L) or thrombin (0.01 U/mL) was used as positive control. The extent of platelet stimulation triggered by CXCL16 was comparable with that found after treatment with ADP ( Figure 2A-2C) .
To test the functional relevance of CXCL16-dependent platelet stimulation for platelet adhesion to the vascular wall, we performed in vitro flow chamber experiments and intravital microscopy after carotid artery ligation. In flow chamber experiments, we found a significantly enhanced platelet adhesion to vascular endothelial cells (HUVEC) under conditions of high arterial shear rates (2000 −s ) after treatment with increasing concentrations of CXCL16 up to 200 ng/mL (53.9 ± 4.0 vs 24.1 ± 2.3; P<0.01; Figure 2D ). Intravital microscopy after carotis ligation was used to study platelet adhesion under conditions of vascular injury in vivo. CXCL16 (200 ng/mL) was found to enhance platelet adhesion to injured vascular wall after carotid ligation (1396 ± 122 vs 768 ± 79; P<0.01; Figure 2E ). In flow chamber experiments, as well as after carotis ligation, we again found a comparable extent of adhesion after stimulation with ADP or CXCL16 ( Figure 2D and 2E).
CXCL16 potentiates platelet activation in response to lowdose ADP stimulation (P-selectin: 95.4 ± 6.4 vs 46.2 ± 4.3; P<0.01; PAC-1: 46.7 ± 6.9 vs 19.4 ± 2.1; P<0.01) but had no further potentiating effect in response to stimulation with low doses of thrombin or collagen-related peptide ( Figure 3A ). CXCL16 alone does not induce platelet aggregation (even in increasing concentrations up to 800 ng/mL; Online Figure I ) but significantly amplifies aggregation after stimulation with low-dose ADP (51.1 ± 3.9 vs 29.3 ± 5.8; P<0.05), an effect that was not found after stimulation with high-dose ADP and stimulation with other agonists such as collagen-related peptide or thrombin ( Figure 3B and 3C ). Furthermore, we could show that CXCL16 triggers fibrinogen-dependent platelet aggregation ( Figure 3D and 3E). Preincubation of washed platelets with CXCL16 (200 ng/mL) for 15 minutes was followed by a significant induction of platelet aggregation after addition of fibrinogen (100 μg/mL) compared with fibrinogen alone (20.4 ± 2.4 vs 4.9 ± 1.8; P<0.01) or CXCL16 (20.4 ± 2.4 vs 3.5 ± 1.9; P<0.01) alone.
In Western blot analysis, CXCL16 significantly increased phosphorylation of Akt at Thr 308 and Ser 473 , which could be prevented by preincubation with PI3K inhibitors Wm (100 nmol/L) and LY (25 μmol/L) ( Figure 4A ). Consistent October 26, 2012 with these findings, the effect of CXCL16 on platelet activation (degranulation, integrin α IIb β 3 activation) was abolished after preincubation with the PI3K inhibitors Wm (P-selectin: 126.0 ± 11.6 vs 52.6 ± 6.4; P<0.01; PAC-1: 30.2 ± 6.6 vs 0.5 ± 0.5; P<0.01) and LY (P-selectin: 126.0 ± 11.6 vs 69.8 ± 10.6; P<0.05; PAC-1: 30.2 ± 6.6 vs 0.8 ± 0.5; P<0.01) as well as by the Akt inhibitor SH-6 (20 μmol/L) (P-selectin: 126.0 ± 11.6 vs 38.4 ± 8.0; P<0.01; PAC-1: 30.2 ± 6.6 vs 1.7 ± 2.1; P<0.01) ( Figure 4B ). The CXCL16induced increase of platelet adhesion to vascular endothelium in vitro after arterial shear stress (2000 −s ) or to injured vascular wall in vivo after carotis ligation was similarly prevented by preincubation with Wm (in vitro: 48 Figure 4F ). The CXCR6 expression was not found to be different in Aktdeficient platelets (Online Figure II) .
For examining whether the effects of CXCL16 on platelet activation attribute to activation and downstream signaling of its receptor CXCR6, we analyzed CXCL16-dependent platelet degranulation and integrin α IIb β 3 activation as well as Akt phosphorylation in cxcr6 −/− and cxcr6 +/+ platelets ( Figure 5 ). As shown in Figure 5A , CXCL16-dependent Akt phosphorylation was abrogated in cxcr6 −/− platelets compared with cxcr6 +/+ platelets. Consequentially, CXCL16-induced platelet degranulation (71.1 ± 9.7 vs 16.9 ± 1.4; P<0.01) and integrin α IIb β 3 activation (169.0 ± 27.8 vs 42.3 ± 16.9; P<0.01) were significantly reduced in cxcr6 −/− platelets compared with cxcr6 +/+ platelets, whereas ADP-dependent platelet activation was unaffected ( Figure 5B ).
To test the role of second-wave mechanisms in potentiating CXCL16-mediated platelet activation, we used the ADPdegrading enzyme apyrase (1.5 U/mL) as well as antagonists of purinergic receptors P 2 Y 1 (MRS2179, 100 μmol/L) and P 2 Y 12 (Cangrelor, 10 μmol/L). For inhibiting platelet thromboxane synthesis, indomethacin (10 μmol/L) was used. As shown in Figure 6A , antagonizing the purinergic receptors, especially 1; P<0.01) , which completely inhibits ADP expression, significantly diminished CXCL16-triggered enhancement of platelet degranulation and integrin α IIb β 3 activation, whereas blockage of thromboxane synthesis was without any significant effect on CXCL16-mediated platelet activation. Similar effects were found when we tested the role of purinergic receptors and its ligand ADP for CXCL16mediated platelet adhesion to intact endothelium (HUVEC monolayer) under arterial shear stress or to injured vascular wall in vivo. As shown before in fluorescence-activated cell sorter analysis, antagonists of purinergic receptors and apyrase potentially inhibited CXCL16-induced platelet adhesion to intact or injured vascular wall under arterial shear stress in vitro (purinergic receptors: 48.2 ± 4.4 vs 26.9 ± 0.9; P<0.01; apyrase: 48.2 ± 4.4 vs 24.6 ± 1.6; P<0.01) and after carotis ligation in vivo (purinergic receptors: 1180 ± 55 vs 428 ± 38; P<0.01; apyrase: 1180 ± 55 vs 811 ± 78; P<0.05), whereas indomethacin again was found to be without effect ( Figure 6B and 6C ).
Discussion
It becomes increasingly evident that platelets are important bidirectional inflammatory effectors linking vascular inflammation, thrombosis, and atherogenesis. 5, 6, 36 Activated platelets present, secrete, and deposit chemokines, thereby exacerbating atherogenesis by inducing recruitment of mononuclear cells to inflammatory lesions of the vascular wall. 7, 14, 37 However chemokines can stimulate platelet activation and adhesion, amplifying the activation-dependent release of proatherogenic and prothrombotic proteins from platelet granula. 6, 36 CXCL16 was shown to be expressed by macrophages, dendritic cells, and lymphocytes in atherosclerotic lesions. 38 Presence of platelet antigens in atherosclerotic lesions raises the possibility that persistent platelet activation may contribute to the progression of atherosclerosis and result in thrombotic complications. 13 Although the role of CXCL16 in atherogenesis is not wellunderstood, increased levels of CXCL16 were found in inflammatory diseases as well as in ACS. 27, 28 Furthermore, high levels of soluble CXCL16 in ACS, usually associated with acute coronary thrombosis, are associated with an increased long-term mortality. 10 Nevertheless, the pathophysiological role of CXCL16 for thrombotic diseases remained unclear. In the present study, we could show for the first time that CXCL16 triggers platelet activation, enhances platelet adhesion, and potentiates platelet aggregation (Figures 2 and 3) , which are major mechanisms underlying thrombotic artery occlusions. 1 CXCL16 binds to its receptor, the 7-transmembrane domain chemokine receptor CXCR6 (BONZO). 16, 19 Recent studies defining CXCL16/CXCR6 as a unique receptor ligand pair excluded unspecific binding of CXCL16 to other receptors. 39 CXCR6 participates in T-cell homing during inflammation, adhesion processes of inflammatory cells, as well as proliferation and invasion of tumor cells, 19 ,40 but has not been described in platelets so far. We could now show that .01 indicate statistically significant difference compared with resting platelets, ##P<0.01 statistically significant difference compared with platelets pretreated with Tyrode buffer instead of CXCL16. B, Arithmetic means±SEM (n=6) of platelet aggregation after preincubation with or without CXCL16 (200 ng/mL) followed by stimulation with ADP (2.5 μmol/L and 10 μmol/L), Thr (0.001 U/mL), or CRP (0.1 μg/mL) are shown. *P<0.05 indicates statistically significant difference compared with platelets pretreated with Tyrode buffer instead of CXCL16. C, Representative tracings of platelet aggregation after stimulation with CXCL16 (200 ng/mL; light gray line) and after preincubation with (dark gray line) or without (black line) CXCL16 followed by stimulation with ADP (2.5 μmol/L). D, Arithmetic means±SEM (n=6) of platelet aggregation in the presence or absence of pretreatment with CXCL16 (200 ng/mL) for 15 minutes (stir speed of 1000 rpm at 37°C) followed by addition of fibrinogen (100 μg/mL) or solvent control for further 15 minutes. **P<0.01 indicates statistically significant difference of fibrinogen-induced platelet aggregation of platelets pretreated with CXCL16 (black bar) compared with platelets pretreated with Tyrode buffer instead of CXCL16 (dark gray bar). ##P<0.01 indicates statistically significant difference between adding fibrinogen (black bar) or solvent control (light gray bar) to CXCL16-pretreated platelets. E, Representative tracings of platelet aggregation before and after addition of fibrinogen (100 μg/mL) to platelets pretreated with CXCL16 (200 ng/mL; black line) or Tyrode buffer (200 ng/mL; dark gray line) and platelet aggregation of CXCL16-pretreated platelets before and after addition of solvent control for fibrinogen (light gray line).
CXCR6 is strongly expressed at mRNA and protein level of human and murine platelets (Figure 1 ). By examinations in cxcr6 −/− platelets, we found that CXCL16-dependent platelet activation critically depends on binding to and signaling via the platelet CXCR6 receptor ( Figure 5 ).
CXCR6-dependent signaling involves the PI3K and Akt pathway. 18, 20 PI3K, as well as its downstream effector Akt, plays a decisive role in the regulation of platelet function. 41 Two isoforms of Akt, Akt1 and Akt2, are expressed in platelets and are described to have similar overlapping functions in platelet activation. 42 Phosphorylation of both Thr 308 and Ser 473 is required for full enzymatic activity. 43 In the present study, we could show that CXCL16 significantly increases phosphorylation of Akt, an effect completely abrogated in CXCR6deficient platelets ( Figure 5A ) and by preincubation of human platelets with LY or Wm ( Figure 4A ), indicating that CXCL16 activates Akt in platelets in a CXCR6-and PI3K-dependent manner. Furthermore, we found a significant reduction of CXCL16-induced platelet degranulation and integrin α IIb β 3 activation after preincubation with the PI3K inhibitors LY (25 μmol/L) and Wm (100 nmol/L), as well as with the Akt inhibitor SH-6 (20 μmol/L) ( Figure 4B ). Akt1 and Akt2 have been shown to be central regulators of platelet secretion and integrin inside-out signaling. 44, 45 Consistent with these findings, platelet activation triggered by CXCL16 was blunted in platelets from mice lacking either Akt1 (akt1 −/− ) or Akt2 (akt2 −/− ) ( Figure 4F ), apparently indicating that both platelet Akt isoforms are involved in downstream signaling of CXCR6. Thus, knockout of 1 of the 2 kinases does not fully abrogate platelet activation induced by CXCR6 ligand CXCL16 ( Figure 4F ). CXCR6 expression itself was not found to be different in Akt-deficient platelets (Online Figure II) .
Enhanced CXCL16 expression has been found in atherosclerotic lesions in apolipoprotein E-deficient mice. 46 Furthermore, it could be shown that CXCL16 appears initially in the endothelium at sites predisposed to atherosclerotic lesion formation without visible lesions promoting monocyte recruitment during early atherogenesis. 47 The finding that CXCL16 induces activation (degranulation and integrin α IIb β 3 activation) of circulating platelets, which in turn could promote release of platelet-derived inflammatory mediators, resulting in enhanced leukocyte recruitment, 48 suggests a vicious circle that potentially aggravates progression of atherogenesis. Mice lacking platelet P-selectin or integrin α IIb have been shown to be protected against development of atherosclerotic lesions, indicating the predominant role of platelets in the initiation of atherogenesis. 34, 49 Activated platelets are able to adhere to intact endothelium, 50 a mechanism that is critically involved in the initiation of early atherosclerotic lesion formation and, moreover, in promoting thrombotic processes dependent on platelet recruitment to the vascular wall. 51 In the present study, we could show that CXCL16 increased platelet adhesion to an HUVEC monolayer under arterial shear stress (2000 −s ) in a PI3K-dependent manner ( Figures 2D and 4C) .
Late stages of atherosclerosis often are associated with thrombotic complications caused by vascular injury and compromised endothelial integrity. 13 Therefore, we investigated the role of CXCL16 in platelet adhesion to injured vascular wall after carotis ligation. As shown in Figure 2E , we found a significant CXCL16-induced upregulation of platelet adhesion after vascular injury. Our results let us speculate that CXCL16 expression in atherosclerotic lesions and release from inflammatory cells could be an additional local proadhesive stimulus for circulating platelets, resulting in increased platelet adhesion at sites of vascular injury.
Platelets express different chemokine receptors, and some chemokines already have been demonstrated to activate platelets. 14, [52] [53] [54] [55] Partly, the activation occurs only in combination with a weak platelet agonist; 53, 54 partly, the activation is independently from costimulation or prestimulation. 52, 55 Although there is evolving evidence that chemokines expressed in atherosclerotic plaques and released from mononuclear cells involved in inflammatory diseases can induce a prothrombotic state via platelet activation, only little is known about signaling pathways and mechanisms mediating these effects. Although CXCL16 is associated with occurrence and severity of thrombotic diseases such as ACS, nothing was known about the role of CXCL16 in platelet activation.
Although classified as a CXC chemokine, CXCL16 shares close structural similarities with CX3CL1 (fractalkine). 20 In recent studies, fractalkine was shown to induce platelet activation, leading to enhanced platelet adhesion in vitro. The authors speculated that ADP or thromboxane synthesis could be involved in fractalkine-dependent platelet stimulation, an effect prevented by apyrase. 55 Platelet activation by ADP is mediated by its 2 purinergic receptors, P 2 Y 1 and P 2 Y 12 , 43 which are furthermore described to participate in mechanisms of platelet adhesion. [56] [57] [58] As shown in Figure 6 , CXCL16-triggered platelet degranulation and integrin α IIb β 3 activation, as well as CXCL16-induced platelet adhesion to vascular wall, were diminished after preincubation with the ADP-degrading enzyme apyrase or the purinergic receptor antagonists MRS2179 and Cangrelor (AR-C69931MX), October 26, 2012
indicating that ADP has a potentiating effect on CXCL16mediated platelet stimulation. Apparently, both P 2 Y 1 and P 2 Y 12 receptors are involved in CXCL16-dependent platelet activation, in which P 2 Y 12 plays the more important role ( Figure 6A ), which is consistent with findings of other studies. 59 However, thromboxane synthesis was not found to be involved because CXCL16-triggered platelet activation was not affected by coincubation with indomethacin ( Figure 6 ). Through purinergic receptor signaling, ADP activates the PI3K/Akt signaling pathway, 60 an effect that could aggravate CXCL16-mediated platelet activation. Akt is a possible candidate for mediating further second-wave signaling by regulating platelet secretory pathways. 42 The second-wave signaling could potentiate CXCL16-induced Akt-dependent triggering of platelet activation. In this way, the phosphorylation of Akt could underlie synergistic effects of CXCL16 and ADP in paracrine/autocrine platelet activation.
In conclusion, the inflammatory chemokine CXCL16 triggers platelet CXCR6-dependent PI3K/Akt signaling, leading to degranulation and integrin α IIb β 3 activation. CXCL16-dependent platelet activation involves ADP-mediated paracrine/autocrine stimulation and fosters platelet adhesion to intact as well as to injured endothelium. Thus, CXCL16 could play a decisive role in linking inflammatory vascular diseases and thrombosis.
What Is Known?
• Platelets represent an important linkage between inflammation and thrombosis. • Specific chemokines are released by inflammatory processes that can influence platelet properties and function, which in turn propagate inflammation.
What New Information Does This Article Contribute?
• The chemokine CXC motif ligand 16 (CXCL16) is critically involved in inflammation-triggered platelet activation and thrombus formation. • The signaling pathway triggered by CXCL16 involves signaling via the CXCL16-sepcific receptor CXC motif receptor 6 and the downstream signal cascade via phosphoinositide 3-kinase and Akt. • CXCL16 induces the release of granule constituents into the microenvironment of activated platelets.
There is growing evidence that platelets play a critical role in the linkage between inflammation and thrombosis; however, the exact underlying mechanisms remain unclear. The present study provides strong evidence that the inflammatory chemokine CXCL16 mediates platelet activation and is a critical link between inflammation and thrombosis. We report for the first time that the functional CXCL16specific receptor CXC motif receptor 6 is strongly expressed on platelet surface, and we elucidated the signaling cascade downstream of the CXC motif receptor 6 receptor involving phosphoinositide 3kinase and Akt. Furthermore, the present study shows that paracrine activation via purinergic receptors is involved in chemokine-triggered platelet activation. Understanding the interaction of CXCL16 with platelets in the milieu of inflammatory diseases may open new avenues for diagnostic and therapeutic strategies for treating cardiovascular disease and other inflammatory disorders Novelty and Significance
